EPAS1 and pulmonary arterial hypertension: Cao et al. (2019) revealed the key role of glycolytic regulatory factor PFKFB3 in the development of Pulmonary hypertension in the rodent Pulmonary hypertension model, and found that the inhibition of cellular PFKFB3 reduced the level of HIF2A, resulting in reduced production of growth factors, pro-inflammatory cytokines and chemokines, inhibition of adhesion molecules and attenuation of Pulmonary hypertension.